Loading clinical trials...

High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors | Clinical Trials | Clareo Health

COMPLETEDPHASE1

High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors

A Pilot Single Arm Study of High-Dose Influenza Vaccine Immunogenicity in Patients With Central Nervous System Tumors

NCT01941758•Wake Forest University Health Sciences

View on ClinicalTrials.gov

Summary

This pilot clinical trial studies high-dose trivalent influenza vaccine in inducing immune response patients with central nervous system tumors. Studying samples of blood in the laboratory from patients receiving trivalent influenza vaccine may help doctors learn more about the effects of trivalent influenza vaccine on cells. It may also help doctors understand how well patients respond to treatment.

Detailed Description

PRIMARY OBJECTIVES: I. To estimate the immunogenicity of high-dose influenza vaccination in patients with central nervous system tumors. SECONDARY OBJECTIVES: I. To assess the geometric mean titer (GMT) in patients after administration of high-dose influenza vaccination compared to previously determined geometric mean titer (GMT) among 38 patients receiving the standard yearly influenza vaccination. II. To assess the seroconversion rates (i.e. four-fold rise in titer) compared to previously determined seroconversion following administration of the standard yearly influenza vaccination. III. To assess the seroprotection rates (i.e. post-vaccination titer \>= 1:40) compared to previously determined seroconversion and seroprotection following administration of the standard yearly influenza vaccination. TERTIARY OBJECTIVES: I. To assess the relationship between serologic markers of immune function and response to high-dose vaccination. OUTLINE: Patients receive trivalent influenza vaccine on day 1. After completion of study, patients are followed up at 28 days and/or 3 months.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients must have a clinical diagnosis of a primary central nervous system tumor
•Patients must be eligible to receive the influenza vaccine
•Patients must be willing to receive the Fluzone® high-dose seasonal influenza vaccine
•Patients must be willing and able to sign an Institutional Review Board (IRB)-approved written informed consent document

Exclusion Criteria

•Patients unable to receive the high-dose influenza vaccine due to history of allergy to egg proteins, allergy to influenza vaccine component, acute febrile illness at the time of proposed vaccine administration, history of clinically or virologically confirmed influenza infection in the previous 6 months, contraindication to intramuscular injections, Guillain-Barré syndrome, or other contraindication to the vaccine
•Patients who have received the 2013-2014 annual influenza vaccine prior to being considered for enrollment on this study

Locations (2)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital

Baltimore, Maryland, United States

Comprehensive Cancer Center of Wake Forest University

Winston-Salem, North Carolina, United States

Key Dates

Start Date

November 1, 2013

Primary Completion Date

November 1, 2014

Completion Date

November 1, 2014

Last Updated

July 5, 2018

Enrollment

ACTUAL participants

Conditions

Central Nervous System Neoplasm

Interventions

trivalent influenza vaccine

BIOLOGICAL

laboratory biomarker analysis

OTHER

Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology

NCT04988009

Central Nervous System NeoplasmLeptomeningeal Neoplasm+2 more

View study

RECRUITINGPHASE2

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

NCT03270059

Central Nervous System NeoplasmCranial Nerve Disorder+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 5, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors

Inclusion Criteria

Exclusion Criteria

Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)